Patients with advanced HR-positive, HER2-negative breast cancer who received cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as a first-line treatment experienced extended progression-free survival compared to those treated in subsequent lines [3]. Here, ERBB2 is linked to breast carcinoma.